NewAmsterdam Pharma (NAMSW) Total Current Liabilities (2022 - 2025)
Historic Total Current Liabilities for NewAmsterdam Pharma (NAMSW) over the last 4 years, with Q3 2025 value amounting to $58.3 million.
- NewAmsterdam Pharma's Total Current Liabilities rose 4124.83% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year increase of 4124.83%. This contributed to the annual value of $106.9 million for FY2024, which is 11427.74% up from last year.
- As of Q3 2025, NewAmsterdam Pharma's Total Current Liabilities stood at $58.3 million, which was up 4124.83% from $36.5 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Total Current Liabilities ranged from a high of $106.9 million in Q4 2024 and a low of $36.2 million during Q4 2022
- For the 4-year period, NewAmsterdam Pharma's Total Current Liabilities averaged around $51.7 million, with its median value being $43.5 million (2023).
- Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 11427.74% in 2024, then plummeted by 3149.88% in 2025.
- Quarter analysis of 4 years shows NewAmsterdam Pharma's Total Current Liabilities stood at $36.2 million in 2022, then surged by 37.92% to $49.9 million in 2023, then skyrocketed by 114.28% to $106.9 million in 2024, then crashed by 45.5% to $58.3 million in 2025.
- Its Total Current Liabilities was $58.3 million in Q3 2025, compared to $36.5 million in Q2 2025 and $40.9 million in Q1 2025.